Brought to you by:
BEST-CLI: A year down the road
A dedicated session at the 2023 VEITHsymposium (Nov. 14–18) in New York City aimed to unpack the ways in which clinical practice and attitudes in the field of chronic limb-threatening ischemia (CLTI) have changed since the BEST-CLI trial was published…
The top 10 most popular Vascular Specialist stories of September 2023
Last month, the most read stories from Vascular Specialist included data releases from the recent Midwestern Vascular Surgical Society (MVSS) using direct revascularization of segmental arteries to prevent spinal cord ischemia; a reflection on the crucial role of vascular nurses during…
New analysis of chronic limb-threatening ischaemia patients places BEST-CLI trial into context within real-world setting
A new analysis of chronic limb-threatening ischaemia (CLTI) treatment outcomes was presented today as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions (SCAI) 2023 Scientific Sessions (18–20 May, Phoenix, USA), a press release reports. Following the initial…
Distal embolic protection linked to significantly better outcomes in carotid stenting
Distal embolic protection using a filter has been associated with improved transfemoral carotid artery stenting (tfCAS) outcomes in terms of in-hospital stroke and death risks—underpinning current Society for Vascular Surgery (SVS) guidelines recommending routine use of distal embolic protection during…
Hispanic adults with PAD access inpatient care most often via the emergency room
Hispanic adults hospitalized for treatment of symptoms of peripheral arterial disease (PAD) were more likely to access this care by going to the emergency room (ER), and they experienced longer and more expensive hospitalizations than non-Hispanic white patients with PAD,…
Combining aspirin with rivaroxaban reduces risk equally in presence or absence of diabetes
In stable atherosclerosis, a combination of aspirin plus rivaroxaban provided a similar relative degree of benefit on coronary, cerebrovascular and peripheral endpoints in patients with and without diabetes, a prespecified analysis of the COMPASS trial has shown. It also noted…